{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T21:19:42Z","timestamp":1780089582135,"version":"3.54.0"},"reference-count":157,"publisher":"Bentham Science Publishers Ltd.","issue":"3","funder":[{"name":"Ministry of Tribal Affairs, Government of India","award":["202122-NFST-AND-00924"],"award-info":[{"award-number":["202122-NFST-AND-00924"]}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CNR"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>There has been a protracted effort to identify reliable targets for migraine.\nIt is believed that each year, hundreds of millions of individuals worldwide suffer from migraines,\nmaking this widespread neurological ailment the second leading cause of years of disability\nworldwide. The rationale of this study is to identify the major targets involved in migraine attacks.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>For this review, specialized databases were searched, such as PubMed, EMBASE, DynaMed\nPlus, and Science Direct databases that included the pathophysiological mechanisms of\nmigraine, focusing on in vitro and in vivo studies in the clinical management of migraine.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Calcitonin gene-related peptide, Pituitary adenylate cyclase-activating polypeptide (PACAP),\nNOD-like receptor Protein (NLRP3), Serotonin, and some other neuroinflammatory biomarkers\nare collectively responsible for the cerebral blood vessel dilation and involved in the nociceptive\npain which leads to migraine attack.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Migraine biomarkers such as CGRP, PACAP, NLRP3, Nitric oxide synthase, MMP9,\nand Serotonin could be targets for developing drugs. Present marketed medications temporarily\nreduce symptoms and pain and have serious cardiovascular side effects. It is suggested that herbal\ntreatment may help prevent migraine attacks without adverse effects. Natural biomolecules that\nmay give better treatment than the present marketed medication and full fledge research should be\ncarried out with natural biomarkers by the Network Pharmacological approach.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1567202620666230721111144","type":"journal-article","created":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T04:37:37Z","timestamp":1690259857000},"page":"296-313","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Major Targets Involved in Clinical Management of Migraine"],"prefix":"10.2174","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0425-9613","authenticated-orcid":true,"given":"Rapuru","family":"Rushendran","sequence":"first","affiliation":[{"name":"Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-\n603 203, Chengalpattu (Dt), Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vellapandian","family":"Chitra","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-\n603 203, Chengalpattu (Dt), Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaliappan","family":"Ilango","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, SRM College of Pharmacy,\nSRM Institute of Science and Technology, Kattankulathur-603 203, Chengalpattu (Dt), Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1474-4422(18)30499-X","volume":"18","author":"Feigin V.L.","year":"2019","unstructured":"Feigin V.L.; Nichols E.; Alam T.; Global, regional, and national burden of neurological disorders, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2019,18(5),459-480","journal-title":"Lancet Neurol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1056\/NEJMra1915327","volume":"383","author":"Messoud A.","year":"2020","unstructured":"Messoud A.; Migraine. N Engl J Med 2020,383(19),1866-1876","journal-title":"N Engl J Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1016\/S1474-4422(19)30185-1","volume":"18","author":"Ashina M.","year":"2019","unstructured":"Ashina M.; Hansen J.M.; Do T.P.; Melo-Carrillo A.; Burstein R.; Moskowitz M.A.; Migraine and the trigeminovascular system-40 years and counting. Lancet Neurol 2019,18(8),795-804","journal-title":"Lancet Neurol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"Steiner T.J.","year":"2020","unstructured":"Steiner T.J.; Stovner L.J.; Jensen R.; Uluduz D.; Katsarava Z.; Migraine remains second among the world\u2019s causes of disability, and first among young women: Findings from GBD2019. J Headache Pain 2020,21(1),137","journal-title":"J Headache Pain"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s10194-022-01402-2","volume":"23","author":"Stovner L.J.","year":"2022","unstructured":"Stovner L.J.; Hagen K.; Linde M.; Steiner T.J.; The global prevalence of headache: An update, with analysis of the influences of methodological factors on prevalence estimates. J Headache Pain 2022,23(1),34","journal-title":"J Headache Pain"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s10194-021-01271-1","volume":"22","author":"Kursun O.","year":"2021","unstructured":"Kursun O.; Yemisci M.; van den Maagdenberg A.M.J.M.; Karatas H.; Migraine and neuroinflammation: The inflammasome perspective. J Headache Pain 2021,22(1),55","journal-title":"J Headache Pain"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/head.13529","volume":"59","author":"Iyengar S.","year":"2019","unstructured":"Iyengar S.; Johnson K.W.; Ossipov M.H.; Aurora S.K.; CGRP and the trigeminal system in migraine. Headache 2019,59(5),659-681","journal-title":"Headache"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"705276","DOI":"10.3389\/fpain.2021.705276","volume":"2","author":"Mungoven T.J.","year":"2021","unstructured":"Mungoven T.J.; Henderson L.A.; Meylakh N.; Chronic migraine pathophysiology and treatment: A review of current perspectives. Front Pain Res 2021,2,705276","journal-title":"Front Pain Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"1744806919867842","DOI":"10.1177\/1744806919867842","volume":"15","author":"Ramachandran R.","year":"2019","unstructured":"Ramachandran R.; Wang Z.; Saavedra C.; Role of Toll-like receptor 4 signaling in mast cell-mediated migraine pain pathway. Mol Pain 2019,15,1744806919867842","journal-title":"Mol Pain"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"e142202","DOI":"10.1172\/JCI142202","volume":"131","author":"Auffenberg E.","year":"2021","unstructured":"Auffenberg E.; Hedrich U.B.S.; Barbieri R.; Hyperexcitable interneurons trigger cortical spreading depression in an Scn1a migraine model. J Clin Invest 2021,131(21),e142202","journal-title":"J Clin Invest"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"100091","DOI":"10.1016\/j.ynpai.2022.100091","volume":"11","author":"Carneiro-Nascimento S.","year":"2022","unstructured":"Carneiro-Nascimento S.; Levy D.; Cortical spreading depression and meningeal nociception. Neurobiol Pain 2022,11,100091","journal-title":"Neurobiol Pain"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1080\/14737175.2021.1947797","volume":"21","author":"Vuralli D.","year":"2021","unstructured":"Vuralli D.; Karatas H.; Yemisci M.; Bolay H.; Updated review on the link between cortical spreading depression and headache disorders. Expert Rev Neurother 2021,21(10),1069-1084","journal-title":"Expert Rev Neurother"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1152\/physrev.00034.2015","volume":"97","author":"Goadsby P.J.","year":"2017","unstructured":"Goadsby P.J.; Holland P.R.; Martins-Oliveira M.; Hoffmann J.; Schankin C.; Akerman S.; Pathophysiology of migraine: A disorder of sensory processing. Physiol Rev 2017,97(2),553-622","journal-title":"Physiol Rev"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1586\/14737175.2013.827472","volume":"13","author":"Akerman S.","year":"2013","unstructured":"Akerman S.; Romero-Reyes M.; Insights into the pharmacological targeting of the trigeminocervical complex in the context of treatments of migraine. Expert Rev Neurother 2013,13(9),1041-1059","journal-title":"Expert Rev Neurother"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"105","DOI":"10.21037\/atm.2016.03.13","volume":"4","author":"Zhang L.M.","year":"2016","unstructured":"Zhang L.M.; Dong Z.; Yu S.Y.; Migraine in the era of precision medicine. Ann Transl Med 2016,4(6),105","journal-title":"Ann Transl Med"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"e474","DOI":"10.1212\/NXG.0000000000000474","volume":"6","author":"Paucar M.","year":"2020","unstructured":"Paucar M.; Granberg T.; Lagerstedt-Robinson K.; SLC1A3 variant associated with hemiplegic migraine and acetazolamide-responsive MRS changes. Neurol Genet 2020,6(4),e474","journal-title":"Neurol Genet"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"5206","DOI":"10.3390\/ijms21155206","volume":"21","author":"Andres-Bilbe A.","year":"2020","unstructured":"Andres-Bilbe A.; Castellanos A.; Pujol-Coma A.; Callejo G.; Comes N.; Gasull X.; The background K+ channel TRESK in sensory physiology and pain. Int J Mol Sci 2020,21(15),5206","journal-title":"Int J Mol Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1212\/01.WNL.0000036617.04943.96","volume":"59","author":"Carlsson A.","year":"2002","unstructured":"Carlsson A.; Forsgren L.; Nylander P.O.; Identification of a susceptibility locus for migraine with and without aura on 6p12.2-p21.1. Neurology 2002,59(11),1804-1807","journal-title":"Neurology"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/j.1526-4610.2011.02040.x","volume":"52","author":"Oterino A.","year":"2012","unstructured":"Oterino A.; Toriello M.; Castillo J.; Family-based association study of chromosome 6p12.2-p21.1 migraine locus. Headache 2012,52(3),393-399","journal-title":"Headache"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"e2012","DOI":"10.1097\/MD.0000000000002012","volume":"94","author":"Chen H.","year":"2015","unstructured":"Chen H.; Ji C.X.; Zhao L.L.; Kong X.J.; Zeng X.T.; Association between polymorphisms of DRD2, COMT, DBH, and MAO-A genes and migraine susceptibility. Medicine 2015,94(47),e2012","journal-title":"Medicine"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/350610a0","volume":"350","author":"Van Tol H.H.M.","year":"1991","unstructured":"Van Tol H.H.M.; Bunzow J.R.; Guan H.C.; Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine. Nature 1991,350(6319),610-614","journal-title":"Nature"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1007\/s100720300005","volume":"23","author":"Mochi M.","year":"2003","unstructured":"Mochi M.; Cevoli S.; Cortelli P.; A genetic association study of migraine with dopamine receptor 4, dopamine transporter and dopamine-beta-hydroxylase genes. Neurol Sci 2003,23(6),301-305","journal-title":"Neurol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1111\/j.1468-1331.2006.01415.x","volume":"13","author":"Cevoli S.","year":"2006","unstructured":"Cevoli S.; Mochi M.; Scapoli C.; A genetic association study of dopamine metabolism-related genes and chronic headache with drug abuse. Eur J Neurol 2006,13(9),1009-1013","journal-title":"Eur J Neurol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"50708","DOI":"10.18632\/oncotarget.9367","volume":"7","author":"Kowalska M.","year":"2016","unstructured":"Kowalska M.; Prendecki M.; Kozubski W.; Lianeri M.; Dorszewska J.; Molecular factors in migraine. Oncotarget 2016,7(31),50708-50718","journal-title":"Oncotarget"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0022-510X(01)00491-9","volume":"186","year":"2001","unstructured":"Y\u0131lmaz M, Erdal ME, Herken H, \u00c7ataloluk O, Barlas \u00d6, Bayaz\u0131t YA. Significance of serotonin transporter gene polymorphism in migraine. J Neurol Sci 2001,186(1-2),27-30","journal-title":"J Neurol Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jns.2011.03.016","volume":"305","author":"Liu H.","year":"2011","unstructured":"Liu H.; Liu M.; Wang Y.; Association of 5-HTT gene polymorphisms with migraine: A systematic review and meta-analysis. J Neurol Sci 2011,305(1-2),57-66","journal-title":"J Neurol Sci"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1177\/0333102410362929","volume":"30","author":"Sch\u00fcrks M.","year":"2010","unstructured":"Sch\u00fcrks M.; Rist P.M.; Kurth T.; 5-HTTLPR polymorphism in the serotonin transporter gene and migraine: A systematic review and meta-analysis. Cephalalgia 2010,30(11),1296-1305","journal-title":"Cephalalgia"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1111\/j.1526-4610.2009.01570.x","volume":"50","author":"Sch\u00fcrks M.","year":"2010","unstructured":"Sch\u00fcrks M.; Rist P.M.; Kurth T.; MTHFR 677C>T and ACE D\/I polymorphisms in migraine: A systematic review and meta-analysis. Headache 2010,50(4),588-599","journal-title":"Headache"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1111\/head.12893","volume":"56","author":"Essmeister R.","year":"2016","unstructured":"Essmeister R.; Kress H.G.; Zierz S.; Griffith L.; Lea R.; Wieser T.; MTHFR and ACE polymorphisms do not increase susceptibility to migraine neither alone nor in combination. Headache 2016,56(8),1267-1273","journal-title":"Headache"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.3390\/metabo12121291","volume":"12","author":"Shahid M.","year":"2022","unstructured":"Shahid M.; Rehman K.; Akash M.S.H.; Genetic polymorphism in angiotensinogen and its association with cardiometabolic diseases. Metabolites 2022,12(12),1291","journal-title":"Metabolites"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1126\/scitranslmed.3005784","volume":"5","author":"Brennan KC","year":"2013","unstructured":"Brennan KC; Bates EA; Shapiro RE; Casein kinase i\u03b4 mutations in familial migraine and advanced sleep phase. Sci Transl Med 2013,5((183):183ra56),1-11","journal-title":"Sci Transl Med"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1111\/head.13154","volume":"57","author":"Chen S.P.","year":"2017","unstructured":"Chen S.P.; Ayata C.; Novel therapeutic targets against spreading depression. Headache 2017,57(9),1340-1358","journal-title":"Headache"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.pharmthera.2012.12.007","volume":"138","author":"Zanger U.M.","year":"2013","unstructured":"Zanger U.M.; Schwab M.; Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 2013,138(1),103-141","journal-title":"Pharmacol Ther"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1517\/14656566.1.3.391","volume":"1","author":"Millson D.S.","year":"2000","unstructured":"Millson D.S.; Tepper S.J.; Rapoport A.M.; Migraine pharmacotherapy with oral triptans: A rational approach to clinical management. Expert Opin Pharmacother 2000,1(3),391-404","journal-title":"Expert Opin Pharmacother"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1046\/j.1365-2362.2000.00633.x","volume":"30","author":"Mattsson P.","year":"2000","unstructured":"Mattsson P.; Bjelfman C.; Lundberg P.O.; Rane A.; Cytochrome P450 2D6 and glutathione S-transferase M1 genotypes and migraine. Eur J Clin Invest 2000,30(4),367-371","journal-title":"Eur J Clin Invest"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000070187","volume":"49","author":"Kusumi M.","year":"2003","unstructured":"Kusumi M.; Ishizaki K.; Kowa H.; Glutathione S-transferase polymorphisms: Susceptibility to migraine without aura. Eur Neurol 2003,49(4),218-222","journal-title":"Eur Neurol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.2174\/18755453MTEyCOTgcx","volume":"22","author":"Guo J.","year":"2021","unstructured":"Guo J.; Zhu X.; Badawy S.; Metabolism and mechanism of human cytochrome P450 enzyme 1A2. Curr Drug Metab 2021,22(1),40-49","journal-title":"Curr Drug Metab"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10194-010-0202-7","volume":"11","author":"Gentile G.","year":"2010","unstructured":"Gentile G.; Missori S.; Borro M.; Sebastianelli A.; Simmaco M.; Martelletti P.; Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 2010,11(2),151-156","journal-title":"J Headache Pain"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/head.12296","volume":"54","author":"Chai N.C.","year":"2014","unstructured":"Chai N.C.; Scher A.I.; Moghekar A.; Bond D.S.; Peterlin B.L.; Obesity and headache: Part I--a systematic review of the epidemiology of obesity and headache. Headache 2014,54(2),219-234","journal-title":"Headache"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1111\/head.12297","volume":"54","author":"Chai N.C.","year":"2014","unstructured":"Chai N.C.; Bond D.S.; Moghekar A.; Scher A.I.; Peterlin B.L.; Obesity and headache: Part II--potential mechanism and treatment considerations. Headache 2014,54(3),459-471","journal-title":"Headache"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1007\/s00125-006-0577-9","volume":"50","author":"Kusminski C.M.","year":"2007","unstructured":"Kusminski C.M.; McTernan P.G.; Schraw T.; Adiponectin complexes in human cerebrospinal fluid: Distinct complex distribution from serum. Diabetologia 2007,50(3),634-642","journal-title":"Diabetologia"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1111\/head.12788","volume":"56","author":"Peterlin B.L.","year":"2016","unstructured":"Peterlin B.L.; Sacco S.; Bernecker C.; Scher A.I.; Adipokines and migraine: A systematic review. Headache 2016,56(4),622-644","journal-title":"Headache"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1177\/0333102417720213","volume":"38","author":"Dom\u00ednguez C.","year":"2018","unstructured":"Dom\u00ednguez C.; Vieites-Prado A.; P\u00e9rez-Mato M.; Role of adipocytokines in the pathophysiology of migraine: A cross-sectional study. Cephalalgia 2018,38(5),904-911","journal-title":"Cephalalgia"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1046\/j.1468-2982.2002.00310.x","volume":"22","author":"Lassen L.H.","year":"2002","unstructured":"Lassen L.H.; Haderslev P.A.; Jacobsen V.B.; Iversen H.K.; Sperling B.; Olesen J.; CGRP may play a causative role in migraine. Cephalalgia 2002,22(1),54-61","journal-title":"Cephalalgia"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1097\/j.pain.0000000000000831","volume":"158","author":"Iyengar S.","year":"2017","unstructured":"Iyengar S.; Ossipov M.H.; Johnson K.W.; The role of calcitonin gene\u2013related peptide in peripheral and central pain mechanisms including migraine. Pain 2017,158(4),543-559","journal-title":"Pain"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1146\/annurev-pharmtox-010814-124701","volume":"55","author":"Russo A.F.","year":"2015","unstructured":"Russo A.F.; Calcitonin gene-related peptide (CGRP): A new target for migraine. Annu Rev Pharmacol Toxicol 2015,55(1),533-552","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14737175.2020.1772758","volume":"20","author":"De Matteis E.","year":"2020","unstructured":"De Matteis E.; Guglielmetti M.; Ornello R.; Spuntarelli V.; Martelletti P.; Sacco S.; Targeting CGRP for migraine treatment: Mechanisms, antibodies, small molecules, perspectives. Expert Rev Neurother 2020,20(6),627-641","journal-title":"Expert Rev Neurother"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/14737175.2021.1951236","volume":"21","author":"Ferreira K.S.","year":"2021","unstructured":"Ferreira K.S.; Dhillon H.; Velly A.M.; The role of a potential biomarker in patients with migraine: Review and new insights. Expert Rev Neurother 2021,21(7),817-831","journal-title":"Expert Rev Neurother"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1080\/14737175.2022.2049758","volume":"22","author":"Scuteri D.","year":"2022","unstructured":"Scuteri D.; Tonin P.; Nicotera P.; Bagetta G.; Corasaniti M.T.; Real world considerations for newly approved CGRP receptor antagonists in migraine care. Expert Rev Neurother 2022,22(3),221-230","journal-title":"Expert Rev Neurother"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1111\/bph.12181","volume":"169","author":"Waschek J.A.","year":"2013","unstructured":"Waschek J.A.; VIP and PACAP: Neuropeptide modulators of CNS inflammation, injury, and repair. Br J Pharmacol 2013,169(3),512-523","journal-title":"Br J Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-018-0844-4","volume":"19","author":"Holland P.R.","year":"2018","unstructured":"Holland P.R.; Barloese M.; Fahrenkrug J.; PACAP in hypothalamic regulation of sleep and circadian rhythm: Importance for headache. J Headache Pain 2018,19(1),20","journal-title":"J Headache Pain"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3389\/fnins.2019.01281","volume":"13","author":"Lindberg P.T.","year":"2019","unstructured":"Lindberg P.T.; Mitchell J.W.; Burgoon P.W.; Pituitary Adenylate Cyclase-Activating Peptide (PACAP)-Glutamate co-transmission drives circadian phase-advancing responses to intrinsically photosensitive retinal ganglion cell projections by suprachiasmatic nucleus. Front Neurosci 2019,13,1281","journal-title":"Front Neurosci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"14848","DOI":"10.1038\/s41598-018-33114-6","volume":"8","author":"Terajima H.","year":"2018","unstructured":"Terajima H.; Yoshitane H.; Yoshikawa T.; Shigeyoshi Y.; Fukada Y.; A-to-I RNA editing enzyme ADAR2 regulates light-induced circadian phase-shift. Sci Rep 2018,8(1),14848","journal-title":"Sci Rep"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/ijms19041020","volume":"19","author":"Rivnyak A.","year":"2018","unstructured":"Rivnyak A.; Kiss P.; Tamas A.; Balogh D.; Reglodi D.; Review on PACAP-induced transcriptomic and proteomic changes in neuronal development and repair. Int J Mol Sci 2018,19(4),1020","journal-title":"Int J Mol Sci"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"444","DOI":"10.3390\/ijms22010444","volume":"22","author":"P\u00f6sty\u00e9ni E.","year":"2021","unstructured":"P\u00f6sty\u00e9ni E.; Kov\u00e1cs-Valasek A.; D\u00e9nes V.; Mester A.; S\u00e9t\u00e1l\u00f3 G.; G\u00e1briel R.; PACAP for retinal health: Model for cellular aging and rescue. Int J Mol Sci 2021,22(1),444","journal-title":"Int J Mol Sci"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.bcp.2018.04.024","volume":"154","author":"Poujol de Molliens M.","year":"2018","unstructured":"Poujol de Molliens M.; L\u00e9tourneau M.; Devost D.; H\u00e9bert T.E.; Fournier A.; Chatenet D.; New insights about the peculiar role of the 28\u201338 C-terminal segment and some selected residues in PACAP for signaling and neuroprotection. Biochem Pharmacol 2018,154,193-202","journal-title":"Biochem Pharmacol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"827","DOI":"10.3390\/ijms21030827","volume":"21","author":"Toth D.","year":"2020","unstructured":"Toth D.; Tamas A.; Reglodi D.; The neuroprotective and biomarker potential of PACAP in human traumatic brain injury. Int J Mol Sci 2020,21(3),827","journal-title":"Int J Mol Sci"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s12031-022-01968-1","volume":"72","author":"Broome S.T.","year":"2022","unstructured":"Broome S.T.; Musumeci G.; Castorina A.; PACAP and VIP mitigate rotenone-induced inflammation in BV-2 microglial cells. J Mol Neurosci 2022,72(11),2163-2175","journal-title":"J Mol Neurosci"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4944","DOI":"10.3390\/ijms20194944","volume":"20","author":"Horvath G.","year":"2019","unstructured":"Horvath G.; Opper B.; Reglodi D.; The Neuropeptide Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is protective in inflammation and oxidative stress-induced damage in the kidney. Int J Mol Sci 2019,20(19),4944","journal-title":"Int J Mol Sci"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"13660","DOI":"10.3390\/ijms222413660","volume":"22","author":"Mandwie M.","year":"2021","unstructured":"Mandwie M.; Karunia J.; Niaz A.; Metformin treatment attenuates brain inflammation and rescues PACAP\/VIP neuropeptide alterations in mice fed a high-fat diet. Int J Mol Sci 2021,22(24),13660","journal-title":"Int J Mol Sci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3389\/fnsys.2017.00090","volume":"11","author":"Girard B.M.","year":"2017","unstructured":"Girard B.M.; Tooke K.; Vizzard M.A.; PACAP\/Receptor system in urinary bladder dysfunction and pelvic pain following urinary bladder inflammation or stress. Front Syst Neurosci 2017,11,90","journal-title":"Front Syst Neurosci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1074\/mcp.RA119.001767","volume":"18","author":"Anapindi K.D.B.","year":"2019","unstructured":"Anapindi K.D.B.; Yang N.; Romanova E.V.; PACAP and other neuropeptide targets link chronic migraine and opioid-induced hyperalgesin mouse models. Mol Cell Proteomics 2019,18(12),2447-2458","journal-title":"Mol Cell Proteomics"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"7125","DOI":"10.1007\/s11033-020-05781-0","volume":"47","author":"P\u00e9rez-Pereda S.","year":"2020","unstructured":"P\u00e9rez-Pereda S.; Toriello-Su\u00e1rez M.; Ocejo-Vinyals G.; Serum CGRP, VIP, and PACAP usefulness in migraine: A case-control study in chronic migraine patients in real clinical practice. Mol Biol Rep 2020,47(9),7125-7138","journal-title":"Mol Biol Rep"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s10194-017-0822-2","volume":"19","author":"Jansen-Olesen I.","year":"2018","unstructured":"Jansen-Olesen I.; Hougaard Pedersen S.; PACAP and its receptors in cranial arteries and mast cells. J Headache Pain 2018,19(1),16","journal-title":"J Headache Pain"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/164_2018_128","volume":"255","author":"Ashina H","year":"2019","unstructured":"Ashina H; Schytz HW; CGRP in human models of migraine. Handb Exp Pharmacol 2019,255,109-20","journal-title":"Handb Exp Pharmacol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s13311-017-0596-x","volume":"15","author":"Vollesen A.L.H.","year":"2018","unstructured":"Vollesen A.L.H.; Amin F.M.; Ashina M.; Targeted pituitary adenylate cyclase-activating peptide therapies for migraine. Neurotherapeutics 2018,15(2),371-376","journal-title":"Neurotherapeutics"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s10194-018-0852-4","volume":"19","author":"Edvinsson L.","year":"2018","unstructured":"Edvinsson L.; Tajti J.; Szal\u00e1rdy L.; V\u00e9csei L.; PACAP and its role in primary headaches. J Headache Pain 2018,19(1),21","journal-title":"J Headache Pain"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.npep.2013.10.010","volume":"47","author":"Kaiser E.A.","year":"2013","unstructured":"Kaiser E.A.; Russo A.F.; CGRP and migraine: Could PACAP play a role too? Neuropeptides 2013,47(6),451-461","journal-title":"Neuropeptides"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1515\/bmc-2014-0008","volume":"5","author":"Onaga T.","year":"2014","unstructured":"Onaga T.; Tachykinin: Recent developments and novel roles in health and disease. Biomol Concepts 2014,5(3),225-243","journal-title":"Biomol Concepts"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1111\/head.13802","volume":"60","author":"Frederiksen S.D.","year":"2020","unstructured":"Frederiksen S.D.; Bekker-Nielsen Dunbar M.; Snoer A.H.; Deen M.; Edvinsson L.; Serotonin and neuropeptides in blood from episodic and chronic migraine and cluster headache patients in case\u2010control and case\u2010crossover settings: A systematic review and meta\u2010analysis. Headache 2020,60(6),1132-1164","journal-title":"Headache"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/952906","volume":"2012","author":"Lakhan S.E.","year":"2012","unstructured":"Lakhan S.E.; Avramut M.; Matrix metalloproteinases in neuropathic pain and migraine: Friends, enemies, and therapeutic targets. Pain Res Treat 2012,2012,1-10","journal-title":"Pain Res Treat"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1586\/ern.09.103","volume":"9","author":"Gupta V.K.","year":"2009","unstructured":"Gupta V.K.; CSD, BBB and MMP-9 elevations: Animal experiments versus clinical phenomena in migraine. Expert Rev Neurother 2009,9(11),1595-1614","journal-title":"Expert Rev Neurother"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1002\/glia.20169","volume":"50","author":"Cunningham L.A.","year":"2005","unstructured":"Cunningham L.A.; Wetzel M.; Rosenberg G.A.; Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005,50(4),329-339","journal-title":"Glia"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12974-020-01778-5","volume":"17","author":"O\u2019Brien W.T.","year":"2020","unstructured":"O\u2019Brien W.T.; Pham L.; Symons G.F.; Monif M.; Shultz S.R.; McDonald S.J.; The NLRP3 inflammasome in traumatic brain injury: Potential as a biomarker and therapeutic target. J Neuroinflammation 2020,17(1),104","journal-title":"J Neuroinflammation"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/s41583-018-0055-7","volume":"19","author":"Heneka M.T.","year":"2018","unstructured":"Heneka M.T.; McManus R.M.; Latz E.; Inflammasome signalling in brain function and neurodegenerative disease. Nat Rev Neurosci 2018,19(10),610-621","journal-title":"Nat Rev Neurosci"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41586-019-1769-z","volume":"575","author":"Ising C.","year":"2019","unstructured":"Ising C.; Venegas C.; Zhang S.; NLRP3 inflammasome activation drives tau pathology. Nature 2019,575(7784),669-673","journal-title":"Nature"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.bbi.2022.11.014","volume":"108","author":"Kodali M.","year":"2022","unstructured":"Kodali M.; Madhu L.N.; Reger R.L.; Intranasally administered human MSC-derived extracellular vesicles inhibit NLRP3-p38\/MAPK signaling after TBI and prevent chronic brain dysfunction. Brain Behav Immun 2022,108,118-134","journal-title":"Brain Behav Immun"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s12079-019-00544-4","volume":"14","author":"Rex D.A.B.","year":"2020","unstructured":"Rex D.A.B.; Agarwal N.; Prasad T.S.K.; Kandasamy R.K.; Subbannayya Y.; Pinto S.M.; A comprehensive pathway map of IL-18-mediated signalling. J Cell Commun Signal 2020,14(2),257-266","journal-title":"J Cell Commun Signal"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12974-020-01736-1","volume":"17","author":"Casili G.","year":"2020","unstructured":"Casili G.; Lanza M.; Filippone A.; Dimethyl fumarate alleviates the nitroglycerin (NTG)-induced migraine in mice. J Neuroinflammation 2020,17(1),59","journal-title":"J Neuroinflammation"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"e05654","DOI":"10.1016\/j.heliyon.2020.e05654","volume":"6","author":"Taheri P.","year":"2020","unstructured":"Taheri P.; Mohammadi F.; Nazeri M.; Nitric oxide role in anxiety-like behavior, memory and cognitive impairments in animal model of chronic migraine. Heliyon 2020,6(12),e05654","journal-title":"Heliyon"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1186\/s12883-021-02434-y","volume":"21","author":"Bandara S.M.R.","year":"2021","unstructured":"Bandara S.M.R.; Samita S.; Kiridana A.M.; Herath H.M.M.T.B.; Elevated nitric oxide and carbon monoxide concentration in nasal-paranasal sinus air as a diagnostic tool of migraine: A case - control study. BMC Neurol 2021,21(1),407","journal-title":"BMC Neurol"},{"key":"ref=82","author":"Pasmanter N.","year":"2023","unstructured":"Pasmanter N.; Iheanacho F.; Hashmi M.F.;  Biochemistry, Cyclic GMP 2023","journal-title":"Biochemistry, Cyclic GMP"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s12974-019-1603-4","volume":"16","author":"Jing F.","year":"2019","unstructured":"Jing F.; Zhang Y.; Long T.; P2Y12 receptor mediates microglial activation via RhoA\/ROCK pathway in the trigeminal nucleus caudalis in a mouse model of chronic migraine. J Neuroinflammation 2019,16(1),217","journal-title":"J Neuroinflammation"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1046\/j.1468-2982.2002.00304.x","volume":"22","author":"D\u2019Amico D.","year":"2002","unstructured":"D\u2019Amico D.; Ferraris A.; Leone M.; Increased plasma nitrites in migraine and cluster headache patients in interictal period: Basal hyperactivity of L-arginine-NO pathway? Cephalalgia 2002,22(1),33-36","journal-title":"Cephalalgia"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/head.12725","volume":"56","author":"Borkum J.M.","year":"2016","unstructured":"Borkum J.M.; Migraine triggers and oxidative stress: A narrative review and synthesis. Headache 2016,56(1),12-35","journal-title":"Headache"},{"key":"ref=86","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1111\/head.13696","volume":"60","author":"Khan F.A.","year":"2020","unstructured":"Khan F.A.; McIntyre C.; Khan A.M.; Maslov A.; Headache and methemoglobinemia. Headache 2020,60(1),291-297","journal-title":"Headache"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1586\/14737175.2015.1001748","volume":"15","author":"Gentile G.","year":"2015","unstructured":"Gentile G.; Negro A.; D\u2019Alonzo L.; Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population. Expert Rev Neurother 2015,15(2),215-225","journal-title":"Expert Rev Neurother"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s10194-023-01572-7","volume":"24","author":"Musubire A.K.","year":"2023","unstructured":"Musubire A.K.; Cheema S.; Ray J.C.; Hutton E.J.; Matharu M.; Cytokines in primary headache disorders: A systematic review and meta-analysis. J Headache Pain 2023,24(1),36","journal-title":"J Headache Pain"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.pathophys.2017.04.001","volume":"24","author":"Khan J.","year":"2017","unstructured":"Khan J.; Noboru N.; Young A.; Thomas D.; Pro and anti-inflammatory cytokine levels (TNF-\u03b1 IL-1\u03b2 IL-6 and IL-10) in rat model of neuroma. Pathophysiology 2017,24(3),155-159","journal-title":"Pathophysiology"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12974-020-1703-1","volume":"17","author":"Jang Y.","year":"2020","unstructured":"Jang Y.; Kim M.; Hwang S.W.; Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception. J Neuroinflammation 2020,17(1),30","journal-title":"J Neuroinflammation"},{"key":"ref=91","doi-asserted-by":"publisher","first-page":"e17360","DOI":"10.1371\/journal.pone.0017360","volume":"6","author":"Neeb L.","year":"2011","unstructured":"Neeb L.; Hellen P.; Boehnke C.; IL-1\u03b2 stimulates COX-2 dependent PGE\u2082 synthesis and CGRP release in rat trigeminal ganglia cells. PLoS One 2011,6(3),e17360","journal-title":"PLoS One"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12974-016-0607-6","volume":"13","author":"Zhou Y.Q.","year":"2016","unstructured":"Zhou Y.Q.; Liu Z.; Liu Z.H.; Interleukin-6: An emerging regulator of pathological pain. J Neuroinflammation 2016,13(1),141","journal-title":"J Neuroinflammation"},{"key":"ref=93","doi-asserted-by":"publisher","first-page":"42791","DOI":"10.1038\/srep42791","volume":"7","author":"Kessler B.","year":"2017","unstructured":"Kessler B.; Rinchai D.; Kewcharoenwong C.; Interleukin 10 inhibits pro-inflammatory cytokine responses and killing of Burkholderia pseudomallei. Sci Rep 2017,7(1),42791","journal-title":"Sci Rep"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1177\/0333102411419022","volume":"31","author":"Sch\u00fcrks M.","year":"2011","unstructured":"Sch\u00fcrks M.; Rist P.M.; Zee R.Y.L.; Chasman D.I.; Kurth T.; Tumour necrosis factor gene polymorphisms and migraine: A systematic review and meta-analysis. Cephalalgia 2011,31(13),1381-1404","journal-title":"Cephalalgia"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1741","DOI":"10.1007\/s10072-018-3493-0","volume":"39","author":"Martami F.","year":"2018","unstructured":"Martami F.; Razeghi Jahromi S.; Togha M.; Ghorbani Z.; Seifishahpar M.; Saidpour A.; The serum level of inflammatory markers in chronic and episodic migraine: A case-control study. Neurol Sci 2018,39(10),1741-1749","journal-title":"Neurol Sci"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"277","DOI":"10.4103\/aian.AIAN_371_18","volume":"22","author":"Han D.","year":"2019","unstructured":"Han D.; Association of serum levels of calcitonin gene-related peptide and cytokines during migraine attacks. Ann Indian Acad Neurol 2019,22(3),277-281","journal-title":"Ann Indian Acad Neurol"},{"key":"ref=97","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1177\/0333102415625614","volume":"37","author":"van Dongen R.M.","year":"2017","unstructured":"van Dongen R.M.; Zielman R.; Noga M.; Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis. Cephalalgia 2017,37(1),49-63","journal-title":"Cephalalgia"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1468-2982.1995.1506489.x","volume":"15","author":"Rothrock J.F.","year":"1995","unstructured":"Rothrock J.F.; Mar K.R.; Yaksh T.L.; Golbeck A.; Moore A.C.; Cerebrospinal fluid analyses in migraine patients and controls. Cephalalgia 1995,15(6),489-493","journal-title":"Cephalalgia"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0143-4179(92)90065-5","volume":"22","author":"V\u00e9csei L.","year":"1992","unstructured":"V\u00e9csei L.; Widerl\u00f6v E.; Ekman R.; Suboccipital cerebrospinal fluid and plasma concentrations of somatostatin, neuropeptide Y and beta-endorphin in patients with common migraine. Neuropeptides 1992,22(2),111-116","journal-title":"Neuropeptides"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"7055","DOI":"10.1007\/s00330-019-06299-1","volume":"29","author":"Meyer M.M.","year":"2019","unstructured":"Meyer M.M.; Schmidt A.; Benrath J.; Cerebral sodium (23Na) magnetic resonance imaging in patients with migraine - a case-control study. Eur Radiol 2019,29(12),7055-7062","journal-title":"Eur Radiol"},{"key":"ref=101","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1111\/j.1526-4610.2006.00722.x","volume":"47","author":"Rozen T.","year":"2007","unstructured":"Rozen T.; Swidan S.Z.; Elevation of CSF tumor necrosis factor alpha levels in new daily persistent headache and treatment refractory chronic migraine. Headache 2007,47(7),1050-1055","journal-title":"Headache"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s12011-019-01931-z","volume":"196","author":"Dolati S.","year":"2020","unstructured":"Dolati S.; Rikhtegar R.; Mehdizadeh A.; Yousefi M.; The role of magnesium in pathophysiology and migraine treatment. Biol Trace Elem Res 2020,196(2),375-383","journal-title":"Biol Trace Elem Res"},{"key":"ref=103","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1177\/0333102410383589","volume":"31","author":"Fonteh A.N.","year":"2011","unstructured":"Fonteh A.N.; Chung R.; Sharma T.L.; Cerebrospinal fluid phospholipase C activity increases in migraine. Cephalalgia 2011,31(4),456-462","journal-title":"Cephalalgia"},{"key":"ref=104","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1097\/WCO.0b013e3283532ca3","volume":"25","author":"Sprenger T.","year":"2012","unstructured":"Sprenger T.; Borsook D.; Migraine changes the brain. Curr Opin Neurol 2012,25(3),252-262","journal-title":"Curr Opin Neurol"},{"key":"ref=105","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s10194-022-01465-1","volume":"23","author":"Gomez-Pilar J.","year":"2022","unstructured":"Gomez-Pilar J.; Mart\u00ednez-Cagigal V.; Garc\u00eda-Azor\u00edn D.; G\u00f3mez C.; Guerrero \u00c1.; Hornero R.; Headache-related circuits and high frequencies evaluated by EEG, MRI, PET as potential biomarkers to differentiate chronic and episodic migraine: Evidence from a systematic review. J Headache Pain 2022,23(1),95","journal-title":"J Headache Pain"},{"key":"ref=106","doi-asserted-by":"publisher","first-page":"e1076","DOI":"10.1212\/WNL.0000000000007047","volume":"92","author":"Dom\u00ednguez C.","year":"2019","unstructured":"Dom\u00ednguez C.; L\u00f3pez A.; Ramos-Cabrer P.; Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine. Neurology 2019,92(10),e1076-e1085","journal-title":"Neurology"},{"key":"ref=107","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1097\/WCO.0000000000001060","volume":"35","author":"Messina R.","year":"2022","unstructured":"Messina R.; Gollion C.; Christensen R.H.; Amin F.M.; Functional MRI in migraine. Curr Opin Neurol 2022,35(3),328-335","journal-title":"Curr Opin Neurol"},{"key":"ref=108","doi-asserted-by":"publisher","first-page":"479","DOI":"10.3390\/toxins12080479","volume":"12","author":"Dom\u00ednguez Vivero C.","year":"2020","unstructured":"Dom\u00ednguez Vivero C.; Leira Y.; Saavedra Pi\u00f1eiro M.; Iron deposits in periaqueductal gray matter are associated with poor response to onabotulinumtoxina in chronic migraine. Toxins 2020,12(8),479","journal-title":"Toxins"},{"key":"ref=109","doi-asserted-by":"publisher","first-page":"233.2-4","DOI":"10.1212\/WNL.0000000000008889","volume":"94","author":"Shubhakaran K.","year":"2020","unstructured":"Shubhakaran K.; Reader response: Iron deposition in periaqueductal gray matter as a potential biomarker for chronic migraine. Neurology 2020,94(5),233.2-4","journal-title":"Neurology"},{"key":"ref=110","doi-asserted-by":"publisher","first-page":"102122","DOI":"10.1016\/j.nicl.2019.102122","volume":"25","author":"Fong C.Y.","year":"2020","unstructured":"Fong C.Y.; Law W.H.C.; Braithwaite J.J.; Mazaheri A.; Differences in early and late pattern-onset visual-evoked potentials between self- reported migraineurs and controls. Neuroimage Clin 2020,25,102122","journal-title":"Neuroimage Clin"},{"key":"ref=111","doi-asserted-by":"publisher","first-page":"e741","DOI":"10.1212\/WNL.0000000000008962","volume":"94","author":"Tu Y.","year":"2020","unstructured":"Tu Y.; Zeng F.; Lan L.; An fMRI-based neural marker for migraine without aura. Neurology 2020,94(7),e741-e751","journal-title":"Neurology"},{"key":"ref=112","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1111\/j.1526-4610.2009.01523.x","volume":"49","author":"Cady R.K.","year":"2009","unstructured":"Cady R.K.; Vause C.V.; Ho T.W.; Bigal M.E.; Durham P.L.; Elevated saliva calcitonin gene-related peptide levels during acute migraine predict therapeutic response to rizatriptan. Headache 2009,49(9),1258-1266","journal-title":"Headache"},{"key":"ref=113","doi-asserted-by":"publisher","first-page":"539","DOI":"10.2165\/11534920-000000000-00000","volume":"24","author":"Durham P.L.","year":"2010","unstructured":"Durham P.L.; Vause C.V.; Calcitonin gene-related peptide (CGRP) receptor antagonists in the treatment of migraine. CNS Drugs 2010,24(7),539-548","journal-title":"CNS Drugs"},{"key":"ref=114","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/j.1526-4610.2010.01657.x","volume":"50","author":"Durham P.L.","year":"2010","unstructured":"Durham P.L.; Vause C.V.; Derosier F.; McDonald S.; Cady R.; Martin V.; Changes in salivary prostaglandin levels during menstrual migraine with associated dysmenorrhea. Headache 2010,50(5),844-851","journal-title":"Headache"},{"key":"ref=115","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1007\/s12035-015-9106-5","volume":"53","author":"Andersen H.H.","year":"2016","unstructured":"Andersen H.H.; Duroux M.; Gazerani P.; Serum MicroRNA signatures in migraineurs during attacks and in pain-free periods. Mol Neurobiol 2016,53(3),1494-1500","journal-title":"Mol Neurobiol"},{"key":"ref=116","doi-asserted-by":"publisher","first-page":"468","DOI":"10.3109\/07853890.2015.1071871","volume":"47","author":"Tafuri E.","year":"2015","unstructured":"Tafuri E.; Santovito D.; de Nardis V.; MicroRNA profiling in migraine without aura: Pilot study. Ann Med 2015,47(6),468-473","journal-title":"Ann Med"},{"key":"ref=117","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s10194-017-0821-3","volume":"18","author":"Ashina H.","year":"2017","unstructured":"Ashina H.; Guo S.; Vollesen A.L.H.; Ashina M.; PACAP38 in human models of primary headaches. J Headache Pain 2017,18(1),110","journal-title":"J Headache Pain"},{"key":"ref=118","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1002\/acn3.113","volume":"1","author":"Zagami A.S.","year":"2014","unstructured":"Zagami A.S.; Edvinsson L.; Goadsby P.J.; Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol 2014,1(12),1036-1040","journal-title":"Ann Clin Transl Neurol"},{"key":"ref=119","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s10194-020-01089-3","volume":"21","author":"Ghanizada H.","year":"2020","unstructured":"Ghanizada H.; Al-Karagholi M.A.M.; Arngrim N.; Investigation of sumatriptan and ketorolac trometamol in the human experimental model of headache. J Headache Pain 2020,21(1),19","journal-title":"J Headache Pain"},{"key":"ref=120","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.1111\/ene.14715","volume":"28","author":"Ashina M.","year":"2021","unstructured":"Ashina M.; Goadsby P.J.; Reuter U.; Long\u2010term efficacy and safety of erenumab in migraine prevention: Results from a 5\u2010year, open\u2010label treatment phase of a randomized clinical trial. Eur J Neurol 2021,28(5),1716-1725","journal-title":"Eur J Neurol"},{"key":"ref=121","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1177\/10600280211023810","volume":"56","author":"Nedd M.","year":"2022","unstructured":"Nedd M.; Garland S.; Falk N.; Wilk A.; Ubrogepant: An oral Calcitonin Gene-Related Peptide (CGRP) receptor antagonist for abortive migraine treatment. Ann Pharmacother 2022,56(3),346-351","journal-title":"Ann Pharmacother"},{"key":"ref=122","first-page":"975","volume":"88","author":"G\u00f6r\u00fcr K","year":"2022","unstructured":"G\u00f6r\u00fcr K; G\u00fcr H; \u0130smi O, \u00d6zcan C, Vayiso\u011flu Y. The effectiveness of propranolol, flunarizine, amitriptyline and botulinum toxin in vestibular migraine complaints and prophylaxis: A non-randomized controlled study. Rev Bras Otorrinolaringol 2022,88(6),975-981","journal-title":"Rev Bras Otorrinolaringol"},{"key":"ref=123","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/S1474-4422(22)00185-5","volume":"21","author":"Ashina M.","year":"2022","unstructured":"Ashina M.; Lanteri-Minet M.; Pozo-Rosich P.; Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): A multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 2022,21(7),597-607","journal-title":"Lancet Neurol"},{"key":"ref=124","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1177\/03331024211053571","volume":"42","author":"Reuter U.","year":"2022","unstructured":"Reuter U.; Ehrlich M.; Gendolla A.; Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 2022,42(2),108-118","journal-title":"Cephalalgia"},{"key":"ref=125","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s10194-022-01415-x","volume":"23","author":"Driessen M.T.","year":"2022","unstructured":"Driessen M.T.; Cohen J.M.; Thompson S.F.; Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain 2022,23(1),56","journal-title":"J Headache Pain"},{"key":"ref=126","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s10194-022-01393-0","volume":"23","author":"Takeshima T.","year":"2022","unstructured":"Takeshima T.; Nakai M.; Shibasaki Y.; Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: Subanalysis of two phase 2b\/3 trials in Japanese and Korean patients. J Headache Pain 2022,23(1),24","journal-title":"J Headache Pain"},{"key":"ref=127","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s10194-020-01088-4","volume":"21","author":"Lipton R.B.","year":"2020","unstructured":"Lipton R.B.; Lombard L.; Ruff D.D.; Trajectory of migraine-related disability following long-term treatment with lasmiditan: Results of the GLADIATOR study. J Headache Pain 2020,21(1),20","journal-title":"J Headache Pain"},{"key":"ref=128","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1177\/03331024211048507","volume":"42","author":"Reuter U.","year":"2022","unstructured":"Reuter U.; Krege J.H.; Lombard L.; Lasmiditan efficacy in the acute treatment of migraine was independent of prior response to triptans: Findings from the CENTURION study. Cephalalgia 2022,42(1),20-30","journal-title":"Cephalalgia"},{"key":"ref=129","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s10194-021-01378-5","volume":"23","author":"Johnston K.","year":"2022","unstructured":"Johnston K.; Harris L.; Powell L.; Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant - post hoc results from an open label safety study (BHV3000\u2013201). J Headache Pain 2022,23(1),10","journal-title":"J Headache Pain"},{"key":"ref=130","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1111\/head.14391","volume":"62","author":"Yonker M.E.","year":"2022","unstructured":"Yonker M.E.; McVige J.; Zeitlin L.; Visser H.; A multicenter, randomized, double\u2010blind, placebo\u2010controlled, crossover trial to evaluate the efficacy and safety of zolmitriptan nasal spray for the acute treatment of migraine in patients aged 6 to 11 years, with an open\u2010label extension. Headache 2022,62(9),1207-1217","journal-title":"Headache"},{"key":"ref=131","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1177\/03331024221093712","volume":"42","author":"Geppetti P.","year":"2022","unstructured":"Geppetti P.; De Cesaris F.; Benemei S.; Self-administered subcutaneous diclofenac sodium in acute migraine attack: A randomized, double-blind, placebo-controlled dose-finding pilot study. Cephalalgia 2022,42(10),1058-1070","journal-title":"Cephalalgia"},{"key":"ref=132","doi-asserted-by":"publisher","first-page":"107151","DOI":"10.1016\/j.clineuro.2022.107151","volume":"214","author":"Hedayat M.","year":"2022","unstructured":"Hedayat M.; Nazarbaghi S.; Heidari M.; Sharifi H.; Venlafaxine can reduce the migraine attacks as well as amitriptyline: A noninferiority randomized trial. Clin Neurol Neurosurg 2022,214,107151","journal-title":"Clin Neurol Neurosurg"},{"key":"ref=133","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1177\/03331024211068813","volume":"42","author":"Najib U.","year":"2022","unstructured":"Najib U.; Smith T.; Hindiyeh N.; Non-invasive vagus nerve stimulation for prevention of migraine: The multicenter, randomized, double-blind, sham-controlled PREMIUM II trial. Cephalalgia 2022,42(7),560-569","journal-title":"Cephalalgia"},{"key":"ref=134","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1080\/01616412.2021.1981105","volume":"44","author":"Sherafat A.","year":"2022","unstructured":"Sherafat A.; Sahebnasagh A.; Rahmany R.; Mohammadi F.; Saghafi F.; The preventive effect of the combination of atorvastatin and nortriptyline in migraine-type headache: A randomized, triple-blind, placebo-controlled trial. Neurol Res 2022,44(4),311-317","journal-title":"Neurol Res"},{"key":"ref=135","doi-asserted-by":"publisher","first-page":"4413","DOI":"10.1007\/s10072-021-05843-6","volume":"43","author":"Matin H.","year":"2022","unstructured":"Matin H.; Taghian F.; Chitsaz A.; Artificial intelligence analysis to explore synchronize exercise, cobalamin, and magnesium as new actors to therapeutic of migraine symptoms: A randomized, placebo-controlled trial. Neurol Sci 2022,43(7),4413-4424","journal-title":"Neurol Sci"},{"key":"ref=136","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1002\/ejp.2027","volume":"26","author":"Peng K.P.","year":"2022","unstructured":"Peng K.P.; J\u00fcrgens T.; Basedau H.; Ortlieb L.; May A.; Sumatriptan prevents central sensitization specifically in the trigeminal dermatome in humans. Eur J Pain 2022,26(10),2152-2161","journal-title":"Eur J Pain"},{"key":"ref=137","first-page":"603","volume":"42","author":"Zai F.L.","year":"2022","unstructured":"Zai F.L.; Ji L.X.; Cheng J.H.; Chen Y.R.; Liu H.; Acupuncture at sphenopalatine ganglion combined with conventional acupuncture for episodic cluster headache: A randomized controlled trial. Zhongguo Zhenjiu 2022,42(6),603-607","journal-title":"Zhongguo Zhenjiu"},{"key":"ref=138","first-page":"498","volume":"42","author":"Cai Y.W.","year":"2022","unstructured":"Cai Y.W.; Pei J.; Fu Q.H.; Electroacupuncture at Siguan points for migraine of liver yang hyperactivity: A randomized controlled trial. Zhongguo Zhenjiu 2022,42(5),498-502","journal-title":"Zhongguo Zhenjiu"},{"key":"ref=139","doi-asserted-by":"publisher","first-page":"2192","DOI":"10.1093\/brain\/awn094","volume":"131","author":"Schoonman G.G.","year":"2008","unstructured":"Schoonman G.G.; van der Grond J.; Kortmann C.; van der Geest R.J.; Terwindt G.M.; Ferrari M.D.; Migraine headache is not associated with cerebral or meningeal vasodilatation-a 3T magnetic resonance angiography study. Brain 2008,131(8),2192-2200","journal-title":"Brain"},{"key":"ref=140","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/164_2018_201","volume":"255","author":"Edvinsson L.","year":"2019","unstructured":"Edvinsson L.; Role of CGRP in migraine. Handb Exp Pharmacol 2019,255,121-130","journal-title":"Handb Exp Pharmacol"},{"key":"ref=141","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.neurol.2021.06.003","volume":"177","author":"Edvinsson L.","year":"2021","unstructured":"Edvinsson L.; CGRP and migraine: From bench to bedside. Rev Neurol 2021,177(7),785-790","journal-title":"Rev Neurol"},{"key":"ref=142","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2022\/6355805","volume":"2022","author":"Yuan H.","year":"2022","unstructured":"Yuan H.; Lu B.; Ji Y.; Role of P2X4\/NLRP3 pathway-mediated neuroinflammation in perioperative neurocognitive disorders. Mediators Inflamm 2022,2022,1-9","journal-title":"Mediators Inflamm"},{"key":"ref=143","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s10194-022-01435-7","volume":"23","author":"Liu J.","year":"2022","unstructured":"Liu J.; Wang G.; Dan Y.; Liu X.; CGRP and PACAP-38 play an important role in diagnosing pediatric migraine. J Headache Pain 2022,23(1),68","journal-title":"J Headache Pain"},{"key":"ref=144","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.2174\/0929867324666170227115019","volume":"24","author":"Tajti J.","year":"2017","unstructured":"Tajti J.; Szok D.; Nagy-Grocz G.; Kynurenines and PACAP in Migraine: Medicinal chemistry and pathogenetic aspects. Curr Med Chem 2017,24(13),1332-1349","journal-title":"Curr Med Chem"},{"key":"ref=145","doi-asserted-by":"publisher","first-page":"341","DOI":"10.18071\/isz.75.0341","volume":"75","author":"Karademir F.","year":"2022","unstructured":"Karademir F.; Ozturk M.; Altunkaynak Y.; Assessment of serum MMP-9, TIMP-1 levels and MMP-9\/TIMP-1 ratio in migraine patients with and without aura. Ideggyogy Sz 2022,75(9-10),341-349","journal-title":"Ideggyogy Sz"},{"key":"ref=146","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.3390\/ph15111402","volume":"15","author":"Arab H.H.","year":"2022","unstructured":"Arab H.H.; Abd El Aal H.A.; Alsufyani S.E.; Topiramate reprofiling for the attenuation of cadmium-induced testicular impairment in rats: Role of NLRP3 inflammasome and AMPK\/mTOR-linked autophagy. Pharmaceuticals 2022,15(11),1402","journal-title":"Pharmaceuticals"},{"key":"ref=147","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s10194-022-01442-8","volume":"23","author":"Wang Y.","year":"2022","unstructured":"Wang Y.; Shan Z.; Zhang L.; P2X7R\/NLRP3 signaling pathway-mediated pyroptosis and neuroinflammation contributed to cognitive impairment in a mouse model of migraine. J Headache Pain 2022,23(1),75","journal-title":"J Headache Pain"},{"key":"ref=148","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41397-019-0133-x","volume":"20","author":"Garc\u00eda-Mart\u00edn E.","year":"2020","unstructured":"Garc\u00eda-Mart\u00edn E.; Navarro-Mu\u00f1oz S.; Rodriguez C.; Association between endothelial nitric oxide synthase (NOS3) rs2070744 and the risk for migraine. Pharmacogenomics J 2020,20(3),426-432","journal-title":"Pharmacogenomics J"},{"key":"ref=149","doi-asserted-by":"publisher","first-page":"105389","DOI":"10.1016\/j.compbiomed.2022.105389","volume":"144","author":"Li X.","year":"2022","unstructured":"Li X.; Wei S.; Niu S.; Network pharmacology prediction and molecular docking-based strategy to explore the potential mechanism of Huanglian Jiedu Decoction against sepsis. Comput Biol Med 2022,144,105389","journal-title":"Comput Biol Med"},{"key":"ref=150","doi-asserted-by":"publisher","first-page":"116384","DOI":"10.1016\/j.jep.2023.116384","volume":"310","author":"Yu S.","year":"2023","unstructured":"Yu S.; Fan C.; Li Y.; Network pharmacology and experimental verification to explore the anti-migraine mechanism of Yufeng Ningxin Tablet. J Ethnopharmacol 2023,310,116384","journal-title":"J Ethnopharmacol"},{"key":"ref=151","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1186\/s12906-017-1933-7","volume":"17","author":"Guilbot A.","year":"2017","unstructured":"Guilbot A.; Bangratz M.; Ait Abdellah S.; Lucas C.; A combination of coenzyme Q10, feverfew and magnesium for migraine prophylaxis: A prospective observational study. BMC Complement Altern Med 2017,17(1),433","journal-title":"BMC Complement Altern Med"},{"key":"ref=152","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/jcm8050652","volume":"8","author":"Anderson N.","year":"2019","unstructured":"Anderson N.; Borlak J.; Hepatobiliary events in migraine therapy with herbs-the case of petadolex, A petasites hybridus extract. J Clin Med 2019,8(5),652","journal-title":"J Clin Med"},{"key":"ref=153","doi-asserted-by":"publisher","first-page":"e20759","DOI":"10.5812\/ircmj.20759","volume":"18","author":"Delavar Kasmaei H.","year":"2016","unstructured":"Delavar Kasmaei H.; Ghorbanifar Z.; Zayeri F.; Effects of coriandrum sativum syrup on migraine: A randomized, triple-blind, placebo-controlled trial. Iran Red Crescent Med J 2016,18(1),e20759","journal-title":"Iran Red Crescent Med J"},{"key":"ref=154","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.jcm.2021.10.002","volume":"20","author":"Martin B.R.","year":"2021","unstructured":"Martin B.R.; Multimodal care for headaches, lumbopelvic pain, and dysmenorrhea in a woman with endometriosis: A case report. J Chiropr Med 2021,20(3),148-157","journal-title":"J Chiropr Med"},{"key":"ref=155","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s10194-022-01405-z","volume":"23","author":"Vuralli D.","year":"2022","unstructured":"Vuralli D.; Arslan B.; Topa E.; Migraine susceptibility is modulated by food triggers and analgesic overuse via sulfotransferase inhibition. J Headache Pain 2022,23(1),36","journal-title":"J Headache Pain"},{"key":"ref=156","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.19082\/6430","volume":"10","author":"Kamali M.","year":"2018","unstructured":"Kamali M.; Seifadini R.; Kamali H.; Mehrabani M.; Jahani Y.; Tajadini H.; Efficacy of combination of Viola odorata, Rosa damascena and Coriandrum sativum in prevention of migraine attacks: A randomized, double blind, placebo- controlled clinical trial. Electron Physician 2018,10(3),6430-6438","journal-title":"Electron Physician"},{"key":"ref=157","doi-asserted-by":"publisher","first-page":"909833","DOI":"10.3389\/fnins.2022.909833","volume":"16","author":"Faridzadeh A.","year":"2022","unstructured":"Faridzadeh A.; Salimi Y.; Ghasemirad H.; Neuroprotective potential of aromatic herbs: Rosemary, sage, and lavender. Front Neurosci 2022,16,909833","journal-title":"Front Neurosci"}],"container-title":["Current Neurovascular Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567202620666230721111144","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/218974\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1567202620666230721111144","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T12:24:08Z","timestamp":1697199848000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/218974\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":157,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1567202620666230721111144","relation":{},"ISSN":["1567-2026"],"issn-type":[{"value":"1567-2026","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2023-06-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-24","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-06-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-13","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}